Skip to content
    PFE
    Earnings call· Jun 2025(Q2 FY25)

    PFIZER Q2 FY25 earnings call PFE

    Aug 5, 2025 Source

    Executive summary

    Pfizer Q2 FY25 — Strong Operational Performance and Pipeline Progress Amid Policy Headwinds

    Pfizer delivered a strong Q2 FY25, driven by robust operational performance across its commercial portfolio and significant advancements in its R&D pipeline. The company raised its full-year adjusted EPS guidance, reflecting efficient cost management and favorable foreign exchange, while navigating policy-related headwinds such as the IRA and potential tariff impacts. Management remains focused on strategic capital allocation and leveraging technology to enhance productivity and expand margins.

    Highlights

    5
    • Adjusted diluted EPS guidance for full year 2025 was raised by $0.10 to a range of $2.90-$3.10.

    • Recently launched and acquired products delivered $4.7 billion in revenue year-to-date, growing approximately 15% operationally year-over-year.

    • Elrexfio showed rapid growth and encouraging progress, with new data demonstrating a confirmed response rate greater than 97% in newly diagnosed multiple myeloma patients.

    • Padcev achieved high year-over-year operational growth of 38% and secured market share greater than 50% in first-line LA metastatic urothelial cancer.

    • Cost improvement initiatives are on track to deliver at least $4.5 billion in cumulative net cost savings from the ongoing cost realignment program by the end of 2025.

    Concerns

    4
    • The company absorbed an $825 million year-over-year unfavorable impact from higher manufacturer discounts due to the IRA Medicare Part D redesign.

    • Guidance for full year 2025 revenue was maintained, partially derisking expected COVID performance in the second half of the year.

    • The company's guidance absorbs the impact of currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes based on a letter from President Trump.

    • IBRANCE experienced declines, partially offsetting strong contributions from other products.

    Guidance & targets

    9
    CategoryTargetConfidence
    Adjusted diluted EPS
    $2.90-$3.10 per share
    high materiality
    High
    Revenue
    $61 billion to $64 billion
    high materiality
    Medium
    Adjusted SI&A expenses
    $13.1 billion to $14.1 billion
    medium materiality
    High
    Adjusted R&D expenses
    $10.4 billion to $11.4 billion
    medium materiality
    High
    Adjusted effective tax rate
    approximately 13%
    medium materiality
    High
    Cumulative net cost savings from cost realignment program
    at least $4.5 billion
    high materiality
    High
    Total cost improvement savings
    approximately $7.7 billion
    high materiality
    High
    Savings from Phase 1 manufacturing optimization program
    $1.5 billion
    medium materiality
    High
    Gross leverage target
    2.7x
    high materiality
    High

    Segment performance

    11
    SegmentRevenueYoYQoQMargin
    International Division
    Growth driven by focus on key assets and new products, with investments concentrated in top 16 markets. Strong performance across geographies and categories.
    Emerging markets growth: 9%China growth: 9%Europe growth: 7%
    6% overall
    Specialty Care
    Contributed to overall international growth.
    9%
    Primary Care
    Driven by Eliquis and vaccines.
    4% (6% excluding COVID)
    Oncology
    Driven by Padcev and other assets.
    6%
    Vyndaqel family
    Strong performance in both U.S. and international markets. U.S. growth driven by improving diagnosis and favorable dynamics, maintaining leadership in first-line treatment-naive patients. International growth due to lower diagnosis rates, expanding access (e.g., UK, Australia, South Korea), and product profile.
    U.S. growth: 15% YoYInternational growth: 32% for the quarterInternational patients treated: 50% increase since beginning of year
    21% operational
    Padcev
    Strong performance driven by growing demand and a one-time favorable impact from a transition to a wholesale distribution model for Seagen products. Standard of care in first-line LA metastatic UC.
    Market share in first-line LA metastatic UC: >50%
    38% operational
    Cibinqo
    Driven by higher demand in the U.S. and growth in key international markets, addressing needs in atopic dermatitis.
    46% operational
    LORBRENA
    Expected continued strength through 2025, emerging as a standard of care for first-line ALK positive metastatic non-small cell lung cancer.
    48% operational
    Braftovi and Mektovi
    Continued momentum, with BREAKWATER trial results showing doubled median overall survival in metastatic colorectal cancer with BRAF V600E mutation.
    23% operational
    XTANDI
    Growing demand for castration-sensitive prostate cancer, top prescribed branded androgen receptor pathway inhibitor. Demonstrated overall survival benefit in metastatic and non-metastatic hormone-sensitive prostate cancer.
    New-to-brand prescription share: 27%
    14% operational
    Recently launched and acquired products (aggregate)
    Year-to-date revenue, expected to fuel top-line growth and largely offset LOEs over the next several years.
    $4.7 billionapproximately 15% operational

    Operational metrics

    10
    Adjusted gross margin
    approximately 76%
    Q2 FY25

    Primarily reflecting product mix within the quarter. Largely achieved percentages in the mid to upper 70s when adjusting for Comirnaty.

    Total adjusted operating expenses
    $5.8 billion8% decline operationally YoY
    Q2 FY25

    Reflects disciplined execution and cost improvement initiatives.

    Shareholder returns via quarterly dividend
    $4.9 billion
    First half 2025

    Part of the capital allocation strategy to maintain and grow the dividend.

    Internal R&D investment
    $4.7 billion
    First half 2025

    Part of the capital allocation strategy to reinvest in the business.

    Gross leverage
    approximately 2.7x
    end of Q2 FY25

    New target, down from 3.25x, reflecting improved cash generation post-Seagen acquisition.

    TCJA repatriating tax payment
    approximately $2.1 billion
    Q2 FY25

    One of the large expected payments impacting Q2 operating cash flows.

    340B program size
    exceed $62 billion
    this year

    Described as a major problem, larger than Medicare and Medicaid combined, with concerns about abuse in the system.

    Nurtec market share
    47%
    Q2 FY25

    Maintained leadership in the oral CGRP class, despite pressures on net revenues from IRA and 340B.

    Pfizer 4.0 cost reduction
    approximately 20%
    ongoing

    Example of how technology is driving efficiency across the commercial business.

    Business development capacity
    approximately $13 billion
    post-3SBio deal

    Following the 3SBio deal, this is the remaining capacity for future transactions.

    Industry KPIs

    12
    MetricValueDetails
    Peak sales guidanceSignificant market opportunities
    Prescription volumeStrong growth
    EPS revenue guidanceAdjusted EPS: $2.90-$3.10; Revenue: $61B-$64BUSD
    Pricing policy impact$825 millionUSD
    Product franchise net salesStrong operational growth across key brands
    Pipeline clinical milestonesMultiple advancements
    Regulatory approvals filingsUpcoming submissions and potential label expansions
    Therapeutic drug market share47%%
    Price volume mix decomposition
    Geographic regional revenue growth6%%
    Clinical trial efficacy safety dataPositive results across multiple assets
    Business development capacity deal appetiteapproximately $13 billionUSD

    Deals & partnerships

    1
    3SBioGlobal ex-China in-licensing agreement for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF.

    Grants Pfizer exclusive rights to develop, manufacture, and commercialize SSGJ-707. Viewed as a promising cancer immunotherapy candidate and a seamless fit within Pfizer's oncology strategy.

    Risks & headwinds

    9
    IRA Medicare Part D redesignQ2 FY25

    $825 million unfavorable impact

    Mitigation: Impact largely in line with expectations, absorbed in guidance. Company is contracting to maintain access for Vyndaqel.

    Tariffs (China, Canada, Mexico)Full Year 2025

    Impact absorbed in guidance

    Mitigation: Strategies implemented to mitigate potential short-term impact; evaluating opportunities and developing plans for long-term mitigation. Active discussions with U.S. administration.

    Potential price changes based on President Trump's letter (MFN)Full Year 2025

    Impact absorbed in guidance

    Mitigation: Active discussions with the U.S. administration to find solutions that balance affordability and industry competitiveness.

    IBRANCE declinesQ2 FY25

    Decline (not quantified)

    Mitigation: Offset by strong contributions from other products in the portfolio.

    Competitive impact of new entrantsongoing

    Not quantified

    Mitigation: Vyndaqel family is differentiated with a strong clinical profile, contributing to continued volume growth. Closely monitoring competitive dynamics.

    Gross-to-net (GTM) pressure on U.S. Vyndaqel performanceH2 FY25

    Not quantified, but expected to impact sequential growth

    Mitigation: Function of Medicare Part D redesign and contracting to maintain 90% access for the brand in Medicare and commercial.

    340B program abuse2025

    Expected to exceed $62 billion this year

    Mitigation: Engaging in discussions with the administration and Congress to address the abuse in the system, aiming to support the program's original intent for small hospitals without allowing excessive markups.

    China emerging superiority in biotechongoing

    China leads in clinical studies, publications (e.g., 42% CRISPR, 62% structural biology), and patent filings.

    Mitigation: Engaging with the administration and Congress to highlight the need to support the U.S. biotech industry to remain competitive, focusing on being better rather than slowing China down.

    IRA negotiations for Ibrance and XTANDIImplementation in 2027

    Hit on NPV is very small

    Mitigation: Both products are losing patent in 2027, so the hit on the company is minimal due to only a few months of exclusivity being affected.

    What to watch in Q3 FY25

    5

    C. diff vaccine Phase III start

    before the end of this year
    CurrentPhase II data announced, preparing for Phase III
    TargetInitiation of Phase III study

    Why it matters

    Successful progression to Phase III is a key de-risking event for this potential first-approved vaccine, addressing a significant unmet medical need.

    Based on these newly announced Phase II data, we are preparing for a Phase III start before the end of this year.

    Q&A highlights

    6

    What are the broad assumptions for the impact of potential MFN price changes and tariffs on revenue/EPS, given the guidance absorbs these? How is the 2025-2026 US fall season for COVID vaccinations being sized, and what progress is being made on payer negotiations?

    Management is in active, productive discussions with the administration regarding MFN and tariffs, but cannot provide specifics due to ongoing negotiations. They believe the underlying business strength allows them to absorb impacts this year. For COVID vaccines, they anticipate an indication for 65+ and those under 64 with medical conditions, no major payer changes, and expect a strong season with robust execution capabilities.

    I'm not in a position to provide much clarity, not because we are not discussing. Right now, we are in very active discussions. I discussed at the highest levels of this government. I discussed myself with the President after he sent the letter, me and all the other.

    asked by Trung Huynh · answered by Albert Bourla

    3 min read5 chapters

    Detailed Narrative

    01

    R&D Pipeline Advancements

    Pfizer highlighted significant progress across its R&D pipeline. Elrexfio, for multiple myeloma, showed rapid growth and encouraging clinical data, with the MagnetisMM-6 Phase III study enrolling well and new data supporting its potential in earlier treatment settings. Sigvotatug Vedotin (SV) for non-small cell lung cancer (NSCLC) has a fully enrolled Phase III monotherapy study with data expected next year, and a Phase III combination study with a PD-1 inhibitor is underway based on promising Phase I results. Hympavzi demonstrated positive Phase III data in hemophilia A or B patients with inhibitors, strengthening its differentiated profile. The second-generation C. difficile vaccine candidate, now in Phase II, showed a fourfold increase in immune response, with Phase III preparations underway for a start by year-end. The Lyme disease vaccine candidate completed dosing, with submission for approval expected next year.

    02

    Commercial Portfolio Performance

    The company's refined commercial strategy is driving higher productivity. The Vyndaqel family delivered 21% year-over-year operational growth, maintaining leadership despite new entrants. Eliquis remains a clear leader in the anticoagulant market, with robust demand and a new direct-to-patient option. Recently launched acquired brands like Nurtec, Padcev, Cibinqo, LORBRENA, Braftovi/Mektovi, and XTANDI are showing strong underlying demand and significant operational growth. Padcev achieved 38% operational growth and over 50% market share in first-line LA metastatic UC, with Phase III readouts for muscle invasive bladder cancer anticipated soon. XTANDI demonstrated long-term overall survival benefits in prostate cancer, contributing to a 27% share in new-to-brand prescriptions.

    03

    Margin Expansion and Cost Management

    Pfizer is making significant strides in expanding margins through various cost improvement initiatives. The ongoing cost realignment program is on track to deliver at least $4.5 billion in cumulative net savings by the end of 2025, with a total target of $7.7 billion by the end of 2027. The Phase 1 manufacturing optimization program is expected to yield $1.5 billion in savings by 2027. These efforts leverage technologies like AI and automation, alongside continued streamlining, contributing to a robust adjusted gross margin of approximately 76% and an 8% operational decline in total adjusted operating expenses in Q2.

    04

    Capital Allocation Strategy

    The company's capital allocation strategy focuses on maintaining and growing its dividend, reinvesting in the business, and making value-enhancing share repurchases. Gross leverage improved to approximately 2.7x, which is now the new target, down from 3.25x, enhancing business development capacity. In the first half of 2025, Pfizer returned $4.9 billion to shareholders via dividends and invested $4.7 billion in internal R&D. The current business development capacity stands at approximately $13 billion, with a preference for smaller, value-driven transactions across oncology, vaccines, internal medicine (including obesity), and immunology.

    05

    Policy and Geopolitical Environment

    Pfizer is actively engaged with policymakers to navigate a complex and rapidly evolving geopolitical environment. The company's guidance absorbs the impact of the IRA Medicare Part D redesign, which resulted in an $825 million unfavorable impact in Q2, as well as potential tariffs and price changes. Discussions with the U.S. administration are ongoing regarding the Most Favored Nation (MFN) policy and tariffs, with a focus on balancing drug affordability with supporting the U.S. biotech industry against competition from China. The 340B program, now exceeding $62 billion annually, is also a key discussion point due to concerns about abuse.

    AI-generated summary of the company’s earnings call. Not investment advice.